Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Giovanella, L, Clark, PM, Chiovato, L, Duntas, L, Elisei, R, Feldt-Rasmussen, U, Leenhardt, L, Luster, M, Schalin-Jäntti, C, Schott, M, Seregni, E, Rimmele, H, Smit, J & Verburg, FA 2014, 'Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper', European journal of endocrinology / European Federation of Endocrine Societies, bind 171, nr. 2, s. R33-46. https://doi.org/10.1530/EJE-14-0148

APA

Giovanella, L., Clark, P. M., Chiovato, L., Duntas, L., Elisei, R., Feldt-Rasmussen, U., Leenhardt, L., Luster, M., Schalin-Jäntti, C., Schott, M., Seregni, E., Rimmele, H., Smit, J., & Verburg, F. A. (2014). Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. European journal of endocrinology / European Federation of Endocrine Societies, 171(2), R33-46. https://doi.org/10.1530/EJE-14-0148

CBE

Giovanella L, Clark PM, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, Leenhardt L, Luster M, Schalin-Jäntti C, Schott M, Seregni E, Rimmele H, Smit J, Verburg FA. 2014. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. European journal of endocrinology / European Federation of Endocrine Societies. 171(2):R33-46. https://doi.org/10.1530/EJE-14-0148

MLA

Vancouver

Author

Giovanella, Luca ; Clark, Penelope M ; Chiovato, Luca ; Duntas, Leonidas ; Elisei, Rossella ; Feldt-Rasmussen, Ulla ; Leenhardt, Laurence ; Luster, Markus ; Schalin-Jäntti, Camilla ; Schott, Matthias ; Seregni, Ettore ; Rimmele, Herald ; Smit, Jan ; Verburg, Frederik A. / Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer : a clinical position paper. I: European journal of endocrinology / European Federation of Endocrine Societies. 2014 ; Bind 171, Nr. 2. s. R33-46.

Bibtex

@article{f744b856482c4064b0524085803647bf,
title = "Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper",
abstract = "Differentiated thyroid cancer (DTC) is the most common endocrine cancer and its incidence has increased in recent decades. Initial treatment usually consists of total thyroidectomy followed by ablation of thyroid remnants by iodine-131. As thyroid cells are assumed to be the only source of thyroglobulin (Tg) in the human body, circulating Tg serves as a biochemical marker of persistent or recurrent disease in DTC follow-up. Currently, standard follow-up for DTC comprises Tg measurement and neck ultrasound combined, when indicated, with an additional radioiodine scan. Measurement of Tg after stimulation by endogenous or exogenous TSH is recommended by current clinical guidelines to detect occult disease with a maximum sensitivity due to the suboptimal sensitivity of older Tg assays. However, the development of new highly sensitive Tg assays with improved analytical sensitivity and precision at low concentrations now allows detection of very low Tg concentrations reflecting minimal amounts of thyroid tissue without the need for TSH stimulation. Use of these highly sensitive Tg assays has not yet been incorporated into clinical guidelines but they will, we believe, be used by physicians caring for patients with DTC. The aim of this clinical position paper is, therefore, to offer advice on the various aspects and implications of using these highly sensitive Tg assays in the clinical care of patients with DTC.",
keywords = "Adenocarcinoma, Follicular, Carcinoma, Humans, Iodine Radioisotopes, Neck, Sensitivity and Specificity, Thyroglobulin, Thyroid Neoplasms, Thyroidectomy, Thyrotropin",
author = "Luca Giovanella and Clark, {Penelope M} and Luca Chiovato and Leonidas Duntas and Rossella Elisei and Ulla Feldt-Rasmussen and Laurence Leenhardt and Markus Luster and Camilla Schalin-J{\"a}ntti and Matthias Schott and Ettore Seregni and Herald Rimmele and Jan Smit and Verburg, {Frederik A}",
note = "{\textcopyright} 2014 The authors.",
year = "2014",
month = aug,
doi = "10.1530/EJE-14-0148",
language = "English",
volume = "171",
pages = "R33--46",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer

T2 - a clinical position paper

AU - Giovanella, Luca

AU - Clark, Penelope M

AU - Chiovato, Luca

AU - Duntas, Leonidas

AU - Elisei, Rossella

AU - Feldt-Rasmussen, Ulla

AU - Leenhardt, Laurence

AU - Luster, Markus

AU - Schalin-Jäntti, Camilla

AU - Schott, Matthias

AU - Seregni, Ettore

AU - Rimmele, Herald

AU - Smit, Jan

AU - Verburg, Frederik A

N1 - © 2014 The authors.

PY - 2014/8

Y1 - 2014/8

N2 - Differentiated thyroid cancer (DTC) is the most common endocrine cancer and its incidence has increased in recent decades. Initial treatment usually consists of total thyroidectomy followed by ablation of thyroid remnants by iodine-131. As thyroid cells are assumed to be the only source of thyroglobulin (Tg) in the human body, circulating Tg serves as a biochemical marker of persistent or recurrent disease in DTC follow-up. Currently, standard follow-up for DTC comprises Tg measurement and neck ultrasound combined, when indicated, with an additional radioiodine scan. Measurement of Tg after stimulation by endogenous or exogenous TSH is recommended by current clinical guidelines to detect occult disease with a maximum sensitivity due to the suboptimal sensitivity of older Tg assays. However, the development of new highly sensitive Tg assays with improved analytical sensitivity and precision at low concentrations now allows detection of very low Tg concentrations reflecting minimal amounts of thyroid tissue without the need for TSH stimulation. Use of these highly sensitive Tg assays has not yet been incorporated into clinical guidelines but they will, we believe, be used by physicians caring for patients with DTC. The aim of this clinical position paper is, therefore, to offer advice on the various aspects and implications of using these highly sensitive Tg assays in the clinical care of patients with DTC.

AB - Differentiated thyroid cancer (DTC) is the most common endocrine cancer and its incidence has increased in recent decades. Initial treatment usually consists of total thyroidectomy followed by ablation of thyroid remnants by iodine-131. As thyroid cells are assumed to be the only source of thyroglobulin (Tg) in the human body, circulating Tg serves as a biochemical marker of persistent or recurrent disease in DTC follow-up. Currently, standard follow-up for DTC comprises Tg measurement and neck ultrasound combined, when indicated, with an additional radioiodine scan. Measurement of Tg after stimulation by endogenous or exogenous TSH is recommended by current clinical guidelines to detect occult disease with a maximum sensitivity due to the suboptimal sensitivity of older Tg assays. However, the development of new highly sensitive Tg assays with improved analytical sensitivity and precision at low concentrations now allows detection of very low Tg concentrations reflecting minimal amounts of thyroid tissue without the need for TSH stimulation. Use of these highly sensitive Tg assays has not yet been incorporated into clinical guidelines but they will, we believe, be used by physicians caring for patients with DTC. The aim of this clinical position paper is, therefore, to offer advice on the various aspects and implications of using these highly sensitive Tg assays in the clinical care of patients with DTC.

KW - Adenocarcinoma, Follicular

KW - Carcinoma

KW - Humans

KW - Iodine Radioisotopes

KW - Neck

KW - Sensitivity and Specificity

KW - Thyroglobulin

KW - Thyroid Neoplasms

KW - Thyroidectomy

KW - Thyrotropin

U2 - 10.1530/EJE-14-0148

DO - 10.1530/EJE-14-0148

M3 - Journal article

C2 - 24743400

VL - 171

SP - R33-46

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -

ID: 44892031